Bernat Olle, Vedanta Biosciences CEO

Pfiz­er-backed Vedan­ta Bio­sciences lands $106M for PhI­II in C. diff, PhII in IBD

Vedan­ta Bio­sciences has se­cured the cash it needs to run a Phase III in Clostrid­ioides dif­fi­cile and a mid-stage tri­al in ul­cer­a­tive col­i­tis, with run­way through 2025, CEO Bernat Olle told End­points News.

The mi­cro­bio­me biotech nabbed $106.5 mil­lion to test whether VE303 can work for pre­vent­ing re­cur­rent C. diff, which leads to in­flam­ma­tion of the colon, with a dif­fer­ent ap­proach than Fer­ring Phar­ma­ceu­ti­cals’ re­cent­ly ap­proved fe­cal-based drug im­plant Re­by­ota and Seres Ther­a­peu­tics’ can­di­date, set for an FDA ap­proval de­ci­sion on Wednes­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters